
BAYER ADR /1/4
Depository Receipt · US0727303028 · 879501 (XFRA)
No Price
Closing Price XFRA 19.12.2025:
8,60 EUR
19.12.2025 17:57
Current Prices from BAYER ADR /1/4
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
![]() Frankfurt |
BAYA.F
|
EUR
|
19.12.2025 07:02
|
8,60 EUR
| 0,05 EUR
+0,58 %
|
![]() Quotrix |
BAGNAS28.DUSD
|
EUR
|
19.12.2025 06:27
|
8,80 EUR
| 0,25 EUR
+2,92 %
|
![]() Düsseldorf |
BAGNAS28.DUSB
|
EUR
|
18.12.2025 18:30
|
8,55 EUR
| -0,35 EUR
-3,93 %
|
UTC |
BAYRY
|
USD
|
08.12.2025 21:00
|
10,10 USD
| 0,43 USD
+4,45 %
|
Company Profile for BAYER ADR /1/4 Depository Receipt
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Company Data
Name BAYER ADR /1/4
Company Bayer AG
Website
https://www.bayer.com
Primary Exchange
Frankfurt
Frankfurt
WKN 879501
ISIN US0727303028
Asset Class Depository Receipt
Sector Healthcare
Industry Drug Manufacturers - General
CEO William N. Anderson
Market Capitalization 40 Mrd.
Country Germany
Currency EUR
Employees 90,6 T
Address Kaiser-Wilhelm-Allee 1, 51368 Leverkusen
IPO Date 1996-11-18
Stock Splits
| Date | Split |
|---|---|
| 20.09.2017 | 4:1 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | BAYRY |
| Düsseldorf | BAGNAS28.DUSB |
| Frankfurt | BAYA.F |
| Quotrix | BAGNAS28.DUSD |
More Shares
Investors who hold BAYER ADR /1/4 also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.





